After hosing Pacira Biosciences CEO Dave Stack at the firm’s London healthcare conference, Jefferies came away with the impression that consensus Exparel estimates for 2024 are too high, while 2025 estimates at $616M are “materially too low.” The firm, which expects shares to re-rate as consensus more appropriately reflects NOPAIN and the market values the stock on 2025 estimates, maintains a Buy and $38 price target on Pacira shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
- Pacira announces FDA approval of expanded EXPAREL label
- Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
- Pacira price target lowered to $50 from $57 at Barclays
- Pacira price target lowered to $57 from $63 at H.C. Wainwright
